3 active not recruiting, 3 recruiting, 2 completed, 2 terminated. 2 Phase 3, 1 Early Phase 1, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Vumerity: new trials by email Literature Review of Vumerity trials Research Report on Vumerity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia Diroximel fumarate (DRF), Placebo - Schizophrenia Disorders | Not applicable | Recruiting | King's College London | 30 | 2025-01-10 | 2026-02-13 |
| Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease Vumerity, Placebo - Peripheral Artery Disease, Peripheral Vascular Diseases | Early Phase 1 | Recruiting | University of Nebraska | 20 | 2024-11-14 | 2026-06-24 |
| A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) - Multiple Sclerosis | Active not recruiting | Biogen | 10500 | 2024-06-08 | 2025-10-16 | |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis | Recruiting | Biogen | 908 | 2023-10-27 | 2026-08-11 | |
| Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) Vumerity, Tecfidera - Multiple Sclerosis (MS) Relapsing Remitting | Active not recruiting | University of Colorado, Denver | 11 | 2023-03-07 | 2026-08-11 | |
| Exploring Diroximel Fumarate Real-world Experience in Canada and Israel Diroximel Fumarate - Relapsing Forms of MS | Terminated | Biogen | 64 | 2021-12-09 | 2023-05-10 | |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants Diroximel fumarate - Healthy Volunteers | Phase 1 | Completed | Biogen | 32 | 2021-12-03 | 2022-07-05 |
| A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel fumarate - Relapsing Forms of Multiple Sclerosis | Phase 3 | Completed | Biogen | 136 | 2021-11-18 | 2025-10-24 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Study of Diroximel Fumarate in the Real-World Setting Diroximel Fumarate - Relapsing Forms of MS | Terminated | Biogen | 75 | 2021-03-01 | 2023-05-26 | |
| Relationship Between Oral DMT Burden and Adherence in MS Cladribine, Dimethyl fumarate, Fingolimod - Multiple Sclerosis, Adherence, Medication | Unknown | Monash University | 323 | 2020-09-25 | 2022-08-31 |
Multiple Sclerosis (6) · Inflammation (1) · Medication Adherence (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Peripheral Arterial Disease (1) · Peripheral Arterial Occlusive Disease 1 (1) · Peripheral Vascular Diseases (1) · Psychotic Disorders (1) · Schizophrenia (1)
Biogen (8) · King's College London (1) · Monash University (1) · University of Colorado, Denver (1) · University of Nebraska (1)
United States (6) · Australia (2) · United Kingdom (2) · China (1) · Germany (1) · Hong Kong (1) · Ireland (1) · Israel (1) · Japan (1) · New Zealand (1) · Spain (1) · Switzerland (1)
Enrique Alvarez, MD/PhD (1) · Ernest Butler, PhD; MD (1) · Gwenael Layec, PhD (1) · Katherine Beck, Clinical Lecturer (1)
2023 (1)